Summary
Access to a precise genetic diagnosis (PrGD) in critically ill newborns is limited and inequitable because complex inclusion criteria used to prioritize testing eligibility omits many patients at high risk for a genetic condition. SeqFirst-neo is a program to test whether a genotype-driven workflow using simple, broad exclusion criteria to assess eligibility for rapid whole genome sequencing (rWGS) increases access to a PrGD in critically ill newborns. All 408 newborns admitted to a neonatal intensive care unit between January 2021 and February 2022 were assessed and of 240 eligible infants, 126 were offered rWGS (i.e., intervention group [IG]) and compared to 114 infants who received conventional care in parallel (i.e., conventional care group [CCG]). A PrGD was made in 62/126 (49.2%) IG neonates compared to 11/114 (9.7%) CCG infants. The odds of receiving a PrGD was ∼9 times greater in the IG vs. the CCG, and this difference was maintained at 12 months follow up. Access to a PrGD in the IG versus CCG differed significantly between infants identified as non-white (34/74, 45.9% vs. 6/29, 20.7%; p=0.024) and Black (8/10, 80.0% vs. 0/4; p=0.015). Neonatologists were significantly less successful at predicting a PrGD in non-white than non-Hispanic white patients. Use of a standard workflow in the IG with a PrGD revealed that a PrGD would have been missed in 26/62 (42%) of infants. Use of simple, broad exclusion criteria that increases access to genetic testing significantly increases access to a PrGD, improves access equity and results in fewer missed diagnoses.
Competing Interest Statement
M. Bamshad is on the Scientific Advisory Board of GeneDx, and has research agreements with GeneDx, Illumina, Inc., and PacBio, Inc. All GeneDx authors are/were employed by and may own stock in GeneDx, Inc. D.L. Veenstra has served as a consultant to Illumina, Inc. D.E. Miller is engaged in a research agreement with Oxford Nanopore Technologies (ONT). ONT has paid for D.E. Miller to travel to speak on their behalf. D.E. Miller holds stock options in MyOme. Other authors declare no competing interests.
Funding Statement
Financial support was provided by grants from GeneDx, the Brotman-Baty Institute, and University of Washington Center for Rare Disease Research (UW-CRDR) with additional contributions from NHGRI grants U01 HG011744, UM1 HG006493, and U24 HG011746. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of University of Washington gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
